RICHMOND, Calif., Oct. 19, 2016 /PRNewswire/ -- Sangamo
BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome
editing, announced today that the company will release its third
quarter 2016 financial results after the market closes on
Wednesday, October 26, 2016. The
press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public
via telephone and webcast. During the conference call, the company
will review the quarter's financial results and discuss other
business matters.
The conference call dial-in numbers are (877) 377-7553 for
domestic callers and (678) 894-3968 for international callers. The
conference ID number for the call is 96289087. Participants may
access the live webcast via a link on the Sangamo BioSciences
website in the Investors Relations section under Events and
Presentations. For those unable to listen in at the designated
time, a conference call replay will be available for one week
following the conference call, from approximately 8:00 p.m. ET on October
26, 2016 to 11:59 p.m. ET on
November 2, 2016. The conference call
replay numbers for domestic and international callers are (855)
859-2056 and (404) 537-3406, respectively. The conference ID number
for the replay is 96289087.
About Sangamo
Sangamo BioSciences, Inc. is focused on
Engineering Genetic Cures® for monogenic and infectious
diseases by deploying its novel zinc finger DNA-binding protein
technology, in therapeutic genome editing and gene regulation, and
AAV-based gene therapy platforms. The Company's proprietary
ZFN-mediated in vivo genome editing approach is focused on
monogenic diseases, including hemophilia and lysosomal storage
disorders. Based on its in vivo genome editing approach,
Sangamo is initiating a Phase 1/2 clinical trial for hemophilia B,
the first in vivo genome editing application cleared by the
FDA. In addition, Sangamo has a Phase 2 clinical program to
evaluate the safety and efficacy of novel ZFP
Therapeutics® for the treatment of HIV/AIDS (SB-728).
The Company has also formed a strategic collaboration with Biogen
Inc. for hemoglobinopathies, such as sickle cell disease and
beta-thalassemia, and with Shire International GmbH to develop
therapeutics for Huntington's disease. It has established strategic
partnerships with companies in non-therapeutic applications of its
technology, including Dow AgroSciences and Sigma-Aldrich
Corporation. For more information about Sangamo, visit the
Company's website at www.sangamo.com.
ZFP Therapeutic® is a registered
trademark of Sangamo BioSciences, Inc.
Logo -
http://photos.prnewswire.com/prnh/20130102/SF35903LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sangamo-biosciences-announces-third-quarter-2016-conference-call-and-webcast-300347671.html
SOURCE Sangamo BioSciences, Inc.